98 related articles for article (PubMed ID: 16893744)
1. Skin Reactions to Immune Checkpoint Inhibitors.
Patel AB; Pacha O
Adv Exp Med Biol; 2017; 995():175-184. PubMed ID: 28321818
[TBL] [Abstract][Full Text] [Related]
2. [Drug-related exanthema under immunotherapy and targeted oncological therapy].
Ziemer M; Livingstone E
Dermatologie (Heidelb); 2024 Jun; 75(6):440-450. PubMed ID: 38772932
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous side effects of new antitumor drugs: clinical features and management.
Gutzmer R; Wollenberg A; Ugurel S; Homey B; Ganser A; Kapp A
Dtsch Arztebl Int; 2012 Feb; 109(8):133-40. PubMed ID: 22419954
[TBL] [Abstract][Full Text] [Related]
4. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines
Lacouture ME; Sibaud V; Gerber PA; van den Hurk C; Fernández-Peñas P; Santini D; Jahn F; Jordan K;
Ann Oncol; 2021 Feb; 32(2):157-170. PubMed ID: 33248228
[No Abstract] [Full Text] [Related]
5. Resveratrol induces long-lasting IL-8 expression and peculiar EGFR activation/distribution in human keratinocytes: mechanisms and implications for skin administration.
Pastore S; Lulli D; Maurelli R; Dellambra E; De Luca C; Korkina LG
PLoS One; 2013; 8(3):e59632. PubMed ID: 23527233
[TBL] [Abstract][Full Text] [Related]
6. Common side effects of anti-EGFR therapy: acneform rash.
Sipples R
Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):28-34. PubMed ID: 16616284
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy and cutaneous toxicities: implications for oncology nurses.
Viale PH
Semin Oncol Nurs; 2006 Aug; 22(3):144-51. PubMed ID: 16893743
[TBL] [Abstract][Full Text] [Related]
8. Clinical breakthroughs in EGFR inhibition: applying the science to your clinical practice.
Morse L
ONS News; 2006; 21(8 Suppl):59-60. PubMed ID: 16925155
[No Abstract] [Full Text] [Related]
9. [Cutaneous side effects of EGFR inhibitors--appearance and management].
Wollenberg A; Kroth J; Hauschild A; Dirschka T
Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
[TBL] [Abstract][Full Text] [Related]
10. EGFR-targeted therapy and related skin toxicity.
Morse L; Calarese P
Semin Oncol Nurs; 2006 Aug; 22(3):152-62. PubMed ID: 16893744
[TBL] [Abstract][Full Text] [Related]
11. What kind of rash is it?: deciphering the dermatologic toxicities of biologic and targeted therapies.
Esper P; Gale D; Muehlbauer P
Clin J Oncol Nurs; 2007 Oct; 11(5):659-66. PubMed ID: 17962174
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
